On November 6, 2012, the FDA approved Xeljanz (tofacitinib). We blogged about the approval of Xeljanz, a JAK inhibitor intended for the treatment of adults with moderate to severe rheumatoid arthritis who've had an inadequate response to methotrexate.
I've put together more information about Xeljanz. Find out how the drug works, how it performed in clinical trials, as well as information about common side effects, warnings, and cost in Xeljanz - What You Need to Know.
Photo by dimshik (stock.xchng)